{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T15:49:47Z","timestamp":1747151387281,"version":"3.40.5"},"reference-count":46,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>A cross\u2010national comparative (CNC) study about opioid utilization would allow the identification of strategies to improve pain management and mitigate risk. However, little is known about the accessibility and validity of information in healthcare databases internationally. This study aimed to identify the feasibility of using healthcare databases to conduct a CNC study of opioid utilization and its associated consequences.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A cross\u2010sectional survey was launched in March 2018, including experts interested in CNC studies comparing opioid utilization by purposeful sampling. An electronic survey was used to collect database characteristics, medicine information, and linkage information of each aggregate\u2010level dataset (AD) and individual patient\u2010level dataset (IPD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, participants from 21 geographical regions reported 18 ADs and 19 IPDs. Information on dispensed medications is available from 17 ADs and 17 IPDs. Of the 16 ADs that include primary care settings, only 9 ADs can obtain information from secondary care settings. Fourteen IPDs included patients' characteristics or could be retrieved from linkage databases. Although most ADs are publicly accessible (<jats:italic>n<\/jats:italic>\u2009=\u200913), only five IPDs can be accessed without extra cost.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Most ADs could be used to report opioid utilization in a primary care setting. IPDs with linkage databases should be applied to identify potential determinants, clinical outcomes, and policy impact. Data access restrictions and governance policies across jurisdictions can be challenging for timely analysis and require further collaboration.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.5618","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T11:31:25Z","timestamp":1679398285000},"page":"1021-1031","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility and validity of using healthcare databases to conduct cross\u2010national comparative studies of opioid use, its determinants and consequences"],"prefix":"10.1002","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9491-0421","authenticated-orcid":false,"given":"Teng\u2010Chou","family":"Chen","sequence":"first","affiliation":[{"name":"Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, School of Health Sciences Faculty of Biology, Medicine and Health, University of Manchester  Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Wettermark","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Uppsala University  Uppsala Sweden"},{"name":"Pharmacy Center, Faculty of Medicine Vilnius University  Vilnius Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Steinke","sequence":"additional","affiliation":[{"name":"Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, School of Health Sciences Faculty of Biology, Medicine and Health, University of Manchester  Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian E.","family":"Caughey","sequence":"additional","affiliation":[{"name":"Registry of Senior Australians, South Australian Health and Medical Research Institute and Division of Health Sciences University of South Australia  Adelaide South Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Tadrous","sequence":"additional","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy University of Toronto  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika J.","family":"Wirtz","sequence":"additional","affiliation":[{"name":"Department of Global Health School of Public Health, Boston University  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li\u2010Chia","family":"Chen","sequence":"additional","affiliation":[{"name":"Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, School of Health Sciences Faculty of Biology, Medicine and Health, University of Manchester  Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Global Opioid Utilization Research Collaborative Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"Global Commission on Drug Policy.The negative impact of drug control on public health: The global crisis of avoidable pain.2015. Accessed June 2018http:\/\/www.globalcommissionondrugs.org\/reports\/the-negative-impact-of-drug-control-on-public-health-the-global-crisis-of-avoidable-pain\/"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e318169d03b"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/09595230500286021"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/injuryprev-2015-041604"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00161-6"},{"key":"e_1_2_12_7_1","unstructured":"Advisory Council on the Misuse of Drugs.Reducing opioid\u2010related deaths in the UK.2016; Accessed July 2020https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/576560\/ACMD-Drug-Related-Deaths-Report-161212.pdf"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/RNJ.0000000000000221"},{"key":"e_1_2_12_9_1","unstructured":"PriceT.Secretary price announces HHS strategy for fighting opioid crisis.2017. Accessed May 2020https:\/\/www.hhs.gov\/about\/leadership\/secretary\/speeches\/2017-speeches\/secretary-price-announces-hhs-strategy-for-fighting-opioid-crisis\/index.html"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(18)30078-1"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00365-4"},{"volume-title":"Cancer pain relief: with a guide to opioid availability","year":"1996","author":"World Health Organization","key":"e_1_2_12_12_1"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118949740.ch14"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2016.01.001"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1191\/0269216305pm1002oa"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2007.10.012"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/15360288.2010.536307"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13564"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2021.2219"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1609216"},{"key":"e_1_2_12_21_1","first-page":"43","article-title":"An international working collaborative to examine global drug utilization: opioid use and misuse","volume":"24","author":"Caughey G","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02164.x"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.4103\/1117-1936.173959"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3896"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92760-Q"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2018.1787"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-016-0198-9"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-017-0492-9"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-004-0801-9"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2018.10.013"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(18)30471-1"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2002.00430.x"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyi060"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1590\/1980-5497201500020005"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2012.07.007"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2013.02.003"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2014.03.009"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000228025.04535.25"},{"key":"e_1_2_12_39_1","first-page":"54","article-title":"A proposed checklist to interpret cross\u2010national comparison studies of drug utilization","volume":"21","author":"Ballar\u00edn E","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1002089"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-8-123"},{"key":"e_1_2_12_42_1","unstructured":"European Monitoring Centre for Drugs and Drug Addiction.Legal topic overviews: classification of controlled drugs.2012. Accessed June 2018http:\/\/www.emcdda.europa.eu\/html.cfm\/index146601EN.html"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.24926\/iip.v6i2.383"},{"key":"e_1_2_12_44_1","unstructured":"Office for National Statistics.Deaths related to drug poisoning in England and Wales 2017 registrations.2018. Accessed July 2020https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/bulletins\/deathsrelatedtodrugpoisoninginenglandandwales\/2017registrations"},{"volume-title":"Cause\u2010of\u2010death classification and definition of drug deaths","year":"2020","author":"Centers for Disease Control and Prevention","key":"e_1_2_12_45_1"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4772"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118949740"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5618","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5618","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T06:09:23Z","timestamp":1692338963000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.5618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1002\/pds.5618"],"URL":"https:\/\/doi.org\/10.1002\/pds.5618","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"type":"print","value":"1053-8569"},{"type":"electronic","value":"1099-1557"}],"subject":[],"published":{"date-parts":[[2023,5,3]]},"assertion":[{"value":"2022-05-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}